Evidence map›Paper›PMID 29769665›Full record

ReviewNature2018

Bioengineering strategies to accelerate stem cell therapeutics.

Christopher M Madl, Sarah C Heilshorn, Helen M Blau

Open access · greenAbstract readReview
In one paragraph

Review in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 3 pooled it
23.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 3 syntheses or guidelines pooled it, 419 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Toxicity Evaluation of TiOFrontiers in bioengineering and biotechnology · 2020
    Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Single-cell transcriptomics identifies PDGFRAInternational journal of oral science · 2025
    Article
  19. Review
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Christopher M MadlBaxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Sarah C HeilshornDepartment of Materials Science and Engineering, Stanford University, Stanford, California, USA.
Helen M BlauBaxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. hblau@stanford.edu.
Stanford University · USBaxter (United States) · US

Funding

Stanford/UNC Biomimetic U19 Research CenterU19AI116484 · NIAID · STANFORD UNIVERSITY · PI AMIEVA, MANUEL R · 2015 to 2025
$13.5M
Stem Cells for Brain and BrawnR01AG020961 · NIA · STANFORD UNIVERSITY · PI BLAU, HELEN M · 2002 to 2019
$5.0M
Telomere extension using nucleoside-modified mRNA and exosomes as a novel therapeR01AR063963 · NIAMS · STANFORD UNIVERSITY · PI BLAU, HELEN M · 2012 to 2016
$4.3M
Learning Regulatory Drivers of Chromatin and Expression Dynamics during Nuclear ReprogrammingR01HG009674 · NHGRI · STANFORD UNIVERSITY · PI BLAU, HELEN M, KUNDAJE, ANSHUL · 2017 to 2019
$2.1M
Mass Cytometry Analysis of Signaling Dysfunction in Duchenne Muscular DystrophyR01NS089533 · NINDS · STANFORD UNIVERSITY · PI BLAU, HELEN M · 2014 to 2017
$1.3M
NHGRI NIH HHS R01 HG009674NIAID NIH HHS U19 AI116484NIAMS NIH HHS R01 AR063963NIA NIH HHS R01 AG020961NIH HHS R01 HG00967401NIH HHS R21 HL13804201NINDS NIH HHS R01 NS089533
6 · The paper itself

Abstract

Although only a few stem cell-based therapies are currently available to patients, stem cells hold tremendous regenerative potential, and several exciting clinical applications are on the horizon. Biomaterials with tuneable mechanical and biochemical properties can preserve stem cell function in culture, enhance survival of transplanted cells and guide tissue regeneration. Rapid progress with three-dimensional hydrogel culture platforms provides the opportunity to grow patient-specific organoids, and has led to the discovery of drugs that stimulate endogenous tissue-specific stem cells and enabled screens for drugs to treat disease. Therefore, bioengineering technologies are poised to overcome current bottlenecks and revolutionize the field of regenerative medicine.

Indexed as

AnimalsBioengineeringCell DifferentiationCell LineageHumansRegenerative MedicineStem CellsStem Cell Transplantation

Identifiers

PMID29769665
PMCPMC6773426
OpenAlexW2800099600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.